Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines Ltd., a Swiss corporation, announced that Pharmacyclics LLC has decided not to appeal a decision by the U.S. Patent and Trademark Office, which invalidated all claims of a Pharmacyclics patent challenged by BeOne. This resolution, confirmed by a joint stipulation to dismiss related litigation, marks the end of the patent dispute, potentially strengthening BeOne’s position in the market.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,355,176
Technical Sentiment Signal: Buy
Current Market Cap: HK$331.1B
See more data about 6160 stock on TipRanks’ Stock Analysis page.